Participants receiving tocilizumab increased visceral adipose tissue mass (Wedell-Neergaard et al., 2018) and showed similar trends for whole body fat mass; therefore on a very speculative note, the augmented glucagon secretion could be secondary to steatosis (Suppli et al., 2016). The gene discussed is GCG; the disease is steatosis.